Koo John, Behnam Shahdad E, Behnam Shahrad M
UCSF Psoriasis Treatment Center, 515 Spruce Street, San Francisco, CA 94143, USA.
Expert Opin Pharmacother. 2003 Dec;4(12):2347-54. doi: 10.1517/14656566.4.12.2347.
Tazarotene (Tazorac, Allergan, Inc.) is the first topical retinoid approved for the treatment of plaque psoriasis. It has a similar onset of action compared to potent topical steroids and has the advantage of a longer remission. The common side effects associated with the drug include skin irritation (including pruritus), erythema and a burning sensation. To overcome some of these shortcomings, it has been used in combination with steroids, calcipotriene and phototherapy. Combination therapy not only results in a decrease in adverse side effects, but also enhanced efficacy. Clinical study data have shown that combination therapy is just as important as tazarotene monotherapy, if not more.
他扎罗汀（Tazorac，艾尔建公司）是首个被批准用于治疗斑块状银屑病的外用维甲酸类药物。与强效外用类固醇相比，其起效时间相似，且具有缓解期更长的优势。与该药物相关的常见副作用包括皮肤刺激（包括瘙痒）、红斑和烧灼感。为克服其中一些缺点，它已与类固醇、卡泊三醇及光疗联合使用。联合治疗不仅能减少不良反应，还能提高疗效。临床研究数据表明，联合治疗即便不比他扎罗汀单药治疗更重要，也同样重要。
